Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

(2011) Yoland Smith et al.   NEUROPSYCHOPHARMACOLOGY

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

(2010) Robert A. Hodgson et al.   EXPERIMENTAL NEUROLOGY

Adenosine, adenosine A2A antagonists, and Parkinson's disease

(2009) P. Jenner et al.   PARKINSONISM & RELATED DISORDERS

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY